Loading…
Loading…
Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 410,769 shares of the biopharmaceutical company's stock, valued at approximately $6,613,000. Bank
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares trading hands. The stock had previously closed at $23.34. Analyst Upgrades and Downgrades Several research analysts recently weighed
Dimensional Fund Advisors LP boosted its holdings in Xencor, Inc. (NASDAQ: XNCR) by 3.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,294,887 shares of the biopharmaceutical company's stock after buying an additional 45,599 shares during the quarter. Dimensional Fund Advisors
Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical pipeline,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “E.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR) (“Xencor”), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the “Settlement Agreement”).Under the Settlement Agreement, Xencor will receive $10.
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.